GeneDx raises Q4 adjusted gross margin view to 68% from 64%

TipRanks

01-14

GeneDx (WGS) Holdings eported preliminary financial results for the fourth quarter and full year of 2024. “2024 was a transformative year for GeneDx, as we achieved our profitability milestone of ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503729615"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503729615\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503729615?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-14 22:25","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2503729615","market":"us","top_or_hot":-1,"title":"GeneDx  raises Q4 adjusted gross margin view to 68% from 64%","media":"TipRanks","content":"<div>\n<p>GeneDx (WGS) Holdings eported preliminary financial results for the fourth quarter and full year of 2024. “2024 was a transformative year for GeneDx, as we achieved our profitability milestone of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/genedx-raises-q4-adjusted-gross-142520425.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GeneDx  raises Q4 adjusted gross margin view to 68% from 64%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGeneDx  raises Q4 adjusted gross margin view to 68% from 64%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-14 22:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/genedx-raises-q4-adjusted-gross-142520425.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>GeneDx (WGS) Holdings eported preliminary financial results for the fourth quarter and full year of 2024. “2024 was a transformative year for GeneDx, as we achieved our profitability milestone of ...</p>\n\n<a href=\"https://finance.yahoo.com/news/genedx-raises-q4-adjusted-gross-142520425.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WGS","symbol_name":"GeneDx Holdings","start_time":0,"source_url":"https://finance.yahoo.com/news/genedx-raises-q4-adjusted-gross-142520425.html","article_id":"2503729615","we_media_id":null,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/genedx-raises-q4-adjusted-gross-142520425.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2503729615","pubTimestamp":1736864720,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. GeneDx price target raised to $118 from $75 at TD Cowen. GeneDx appoints Bryan Dechairo as COO, effective immediately","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"WGS":"GeneDx Holdings","BK4196":"保健护理服务","WGSWW":"GENEDX HOLDINGS CORP C/WTS 22/07/2026 (TO PUR COM)"},"translate_title":"GeneDx将第四季度调整后毛利率预期从64%上调至68%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WGS":0.9,"WGSWW":0.9},"content_text":"GeneDx (WGS) Holdings eported preliminary financial results for the fourth quarter and full year of 2024. “2024 was a transformative year for GeneDx, as we achieved our profitability milestone of adjusted net income, released landmark studies, strengthened our products and expanded our team to set up for the opportunity ahead,” said Katherine Stueland, CEO of GeneDx. “The economic burden of rare disease is estimated to be $1 trillion annually, with the absence of early diagnosis being a major contributor to this cost and the cause for unnecessary and avoidable suffering faced by too many families. With our differentiated capabilities, GeneDx is setting the standard for the use of genetics in healthcare. We ended 2024 with momentum and are only beginning to unlock our full potential.” “Our Q4 performance reflects strong execution as we expect to deliver a second consecutive quarter of adjusted net income and our first quarter of positive operational cash flow,” said Kevin Feeley, CFO of GeneDx. Management expects GeneDx to report: Revenues of at least $299M for full year 2024, an increase of 54% year-over-year vs previous guidance was $284-$290M. Consensus $288.2M.. Revenues of at least $92M in the fourth quarter 2024, an increase of 59% year-over-year and 20% sequentially, Consensus $80.22M …\n\nStay Ahead of the Market:\n\nDiscover outperforming stocks and invest smarter with Top Smart Score Stocks\nFilter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener\n\n\n\nPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>\n\n\nSee the top stocks recommended by analysts >>\n\n\nRead More on WGS:\n\nGeneDx Holdings Expects Strong 2024 Financial Performance\nGeneDx management to meet with BTIG\nGeneDx price target raised to $118 from $75 at TD Cowen\nGeneDx Holdings Appoints Bryan Dechairo as COO\nGeneDx appoints Bryan Dechairo as COO, effective immediately","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}